| aromatic amino acid hydroxylase, aromatic amino acid, aromatic | |
| arrestin, arsenic, arsenical |
| aromatic-L-amino-acid decarboxylase | |||||||
|---|---|---|---|---|---|---|---|
| Ribbon diagram of a domestic pig DOPA decarboxylase dimer.[1] | |||||||
| Identifiers | |||||||
| EC number | 4.1.1.28 | ||||||
| CAS number | 9042-64-2 | ||||||
| Databases | |||||||
| IntEnz | IntEnz view | ||||||
| BRENDA | BRENDA entry | ||||||
| ExPASy | NiceZyme view | ||||||
| KEGG | KEGG entry | ||||||
| MetaCyc | metabolic pathway | ||||||
| PRIAM | profile | ||||||
| PDB structures | RCSB PDB PDBe PDBsum | ||||||
| Gene Ontology | AmiGO / EGO | ||||||
|
|||||||
| DOPA decarboxylase (aromatic L-amino acid decarboxylase) | |
|---|---|
| Identifiers | |
| Symbol | DDC |
| Entrez | 1644 |
| HUGO | 2719 |
| OMIM | 107930 |
| RefSeq | NM_000790 |
| UniProt | P20711 |
| Other data | |
| EC number | 4.1.1.28 |
| Locus | Chr. 7 p11 |
Aromatic L-amino acid decarboxylase (EC 4.1.1.28, synonyms: DOPA decarboxylase, tryptophan decarboxylase, 5-hydroxytryptophan decarboxylase, AAAD) is a lyase enzyme.
|
Contents
|
It catalyzes several different decarboxylation reactions:
The enzyme uses pyridoxal phosphate, the active form of vitamin B6, as a cofactor.
In normal dopamine and serotonin (5-HT) neurotransmitter synthesis, AAAD is not the rate-limiting step in either reaction. However, AAAD becomes the rate-limiting step of dopamine synthesis in patients treated with L-DOPA (such as in Parkinson's Disease), and the rate-limiting step of serotonin synthesis in people treated with 5-HTP (such as in mild depression or dysthymia). AAAD is inhibited by Carbidopa outside of the blood brain barrier to inhibit the premature conversion of L-DOPA to Dopamine in the treatment of Parkinson's.
AAAD is the rate-limiting enzyme in the formation of biogenic trace amines.
Click on genes, proteins and metabolites below to link to respective articles. [2]
The gene encoding the enzyme is referred to as DDC and located on chromosome 7 in humans.[3] Single nucleotide polymorphisms and other gene variations have been investigated in relation to neuropsychiatric disorders, e.g., a one-base pair deletion at –601 and a four-base pair deletion at 722–725 in exon 1 in relation to bipolar disorder[4] and autism.[5]
|
|||||||||||||||||||||||||||
This entry is from Wikipedia, the leading user-contributed encyclopedia. It may not have been reviewed by professional editors (see full disclaimer)